New method to measure the carbamoylating activity of nitrosoureas by electron paramagnetic resonance spectroscopy

Free Radical Research

Volumn 27, Issue 2, 1997, Pages 197-206

  Gadzheva, Vesselina ^a   Ichimori, Kohji ^b   Raikov, Zahari ^a   Nakazawa, Hiroe ^b  

^a Trakia University Medical College   (Bulgaria)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

Anticancer drug; Carbamoylating activity; Carbamoylation; EPR; Nitrosourea; Nitroxide

Indexed keywords

CARMUSTINE; ISOCYANIC ACID DERIVATIVE; LOMUSTINE; NITROSOUREA DERIVATIVE; PIPERIDINE DERIVATIVE;

ARTICLE; CHEMICAL MODIFICATION; ELECTRON SPIN RESONANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TECHNIQUE;

EID: 0030817304     PISSN: 10715762     EISSN: None     Source Type: Journal    
DOI: 10.3109/10715769709097852     Document Type: Article

References (24)

1. Carter, S. K., Schabel, Jr., F. M., Broder, L. E. and Johnston, T. P. (1988). 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and other nitrosoureas in cancer treatment. A review. Advance in Cancer Research, 16, 273-332.
2. Tranchand, B., Lucas, C., Biron, P., Giroux, B., Gordon, B., Richards, R., Solere, P., Roux, N., Evene, E., Mornex, F, Clavel, M. and Ardiet, C. (1993). Phase I pharmaokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas. Cancer Chemistry and Pharmacology, 32, 46-52.
3. Bibby, M. C., Loadman, P. M., Al-Ghabban, A. F. and Double, J. A. (1992). Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice. British Journal of Cancer, 65, 347-350.
4. Kim-Triana, B., Misset, J. L, Madelmont, J. C., Godeneche, D., Musset, M. and Mathe, G. (1992). Phase I trial of Perrimustine, a new cysteamine (2-Chloroethyl) nitrosourea: an intrapatient escalation scheme. Anticancer Drugs, 3, 225-231.
5. Weiss, R. B., Poster, D. S. and Penta, J. S. (1981). The nitrosoureas and pulmonary toxicity. Cancer Treatment Review, 8, 111-125.
6. Sosnovsky, G. and Rao, N. U. M. (1991). In the search for new anticancer drugs. XXIII: Exploration of a predictive design for anticancer drugs of carbohydrates containing N-nitrosochloroethylamino, N-nitrosoethyl, and N-nitrosoaminoxyl components. Journal of Pharmacological Science, 80, 693-699.
7. Sosnovsky, G., Prakash, I. and Rao, N. U. M. (1993). In the search for new anticancer drugs. XXIV: Synthesis and anticancer activity of amino acids and dipeptides containing the 2-chloroethyl- and N′-(2-chloroethyl)-N′-nitroso-aminocarbonyl groups. Journal of Pharmacological Science, 82, 1-10.
8. Eisenbrand, G., Berger, M. R., Fisher, J., Schneider, M. R., Tang, W. and Zeller, W. J. (1988). Development of more selective anti-cancer nitrosoureas. Anticancer Drug Design, 2, 351-359.
9. Raikov, Z., Todorov, D., Ilarionova, M., Demirov, G., Tsanova, Ts. and Kafalieva, D. (1985). Synthesis and study of spin-labeled nitrosoureas. Cancer Biochemistry and Biophysics, 7, 343-348.
10. Montgomery, J. A. and Johnston, T. P. (1990). Nitrosoureas. In: The Chemistry of Antitumor Agents (ed. D. E. V. Wilman), Glasgow, London, Blackie, pp 131-158.
11. Bedford, P. and Eisenbrand, G. (1984). DNA-damage and repair in the bone marrow of rats treated with four chloroethylnitrosoureas. Cancer Research, 44, 514-518.
12. Chang, T. K., Chen, H. and Waxman, D. J. (1994). 1-(2-choloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) modulates rat liver microsomal cyclophosphamide and ifosphamide activation by suppressing cytochrome P450 2C11 messenger RNA levels. Drug Metabolism and Disposition, 22, 673-679.
13. Wheeler, G. P., Bowdon, B. J., Grimsley, J. A. and Lloyd, H. H. (1974). Interrelationships of some chemical, physicochemical and biological activities of several 1-(2-haloethyl)-1-nitrosourea and related compounds. Cancer Research, 34, 194-200.
14. Brubaker, Jr, W. F., Zhao, H.-P. and Prusoff, W. H. (1986). Measurement of carbamoylating activity of nitrosoureas and isocyanates by a novel high-pressure liquid chromatography assay. Biochemical Pharmacology, 35, 2359-2365.
15. Sosnovsky, G. (1990). The quest for a predictive design of anticancer drugs. Pure Applied Chemistry, 62, 289-294.
16. Gadzheva, V. G. and Raikov, Z. D. (1991). SLCNCH. Drug Data Report, 13, 344.
17. Gadjeva, V., Ilarionova, M., Raikov, Z. and Todorov, D. (1991). Biological activity and toxicity of new 1-alkyl-1-nitroso-3-cyclohexyl-urea analogues of CCNU. Oncologia, 3, 18-22.
18. Zar, J. H. (1984). Biostatistical Analysis, Prentice-Hall, Englewood Cliffs, NJ 07632, pp 162-191.
19. Swarts, H. M. (1990). The use of nitroxides in viable biological systems: an opportunity and challenge for chemists and biochemists. Pure Applied Chemistry, 62, 235-239.
20. Sosnovsky, G., Li, S. W. and Rao, N. U. M. (1987). In the search for new anticancer drugs XXI: Spin labeled nitrosoureas. Zeitschrift für Naturforschung 42C, 921-931.
21. Gadzheva, V., Ichimori, K., Nakazawa, H. and Raikov, Z. (1994). Superoxide scavenging activity of spin-labeled nitrosourea and triazene derivatives. Free Radical Research, 21, 177-186.
22. Zheleva, A., Raikov, Z., Ilarinova, M. and Todorov, D. (1995). Spin labeled amino acid nitrosourea derivatives - synthesis and antitumour activity. Pharmazie, 50, 25-26.
23. Metzner, E. K., Libertini, L. J. and Calvin, M. (1974). Spin exchange in nitroxyl biradicals. Journal of American Chemical Society, 96, 6515-6516.
24. Becker, K. and Schirmer, R. H. (1995). 1,3-Bis(2-chloroethyl)-1-nitrosourea as thiol-carbamoylating agent in biological systems. Methods in Enzymology, 251, 173-188.